Lv62
2675 积分 2022-12-12 加入
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers
1个月前
已完结
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
1个月前
已完结
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
1个月前
已完结
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
1个月前
已完结
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
1个月前
已完结
MTAP deficiency confers resistance to cytosolic nucleic acid sensing and STING agonists
1个月前
已完结
PARP inhibitors: Synthetic lethality in the clinic
1个月前
已完结
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
1个月前
已完结
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
1个月前
已完结
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
1个月前
已完结
皖公网安备34019202002308
